[Unstable angina pectoris: coagulation disorder and its therapy].
The initiating event in unstable angina is plaque rupture. It triggers platelet activation and aggregation, leading to the formation of an intracoronary thrombus, which can be detected on autopsy, angiography, and by fiber-optic coronary angioscopy. Biochemical markers of platelet and thrombin activity are usually increased and support the pathophysiologic role of coronary thrombosis in unstable angina. Aspirin and heparin have been shown to be effective, whereas thrombolytic therapy has no beneficial clinical effect. Newer specific antithrombotic drugs (hirudin, hirulog) and GPIIb/IIIa platelet receptor inhibitors are being tested in clinical trials and seem to provide a new dimension for the treatment of acute coronary syndromes.
Meyer
B J
BJ
Cardiac Unit, Massachusetts General Hospital, Boston.
D000789:Angina, Unstable / Q000097:blood* / Q000188:drug therapy; D001778:Blood Coagulation Disorders / Q000097:blood* / Q000188:drug therapy; D003328:Coronary Thrombosis / Q000097:blood / Q000188:drug therapy; D006493:Heparin / Q000627:therapeutic use; D024764:Hirudin Therapy; D006629:Hirudins / Q000031:analogs & derivatives; D006801:Humans; D010446:Peptide Fragments / Q000627:therapeutic use; D015539:Platelet Activation / Q000187:drug effects; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use; D013917:Thrombin / Q000037:antagonists & inhibitors
D006629:Hirudins; D010446:Peptide Fragments; D010975:Platelet Aggregation Inhibitors; D011994:Recombinant Proteins; D006493:Heparin; D013917:Thrombin; C074619:bivalirudin
Instabile Angina pectoris: Gerinnungsstörung und ihre Therapie.